Ratings by Berenberg (Kerry Holford)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/12/2026 | Novo Nordisk | NVO | Downgrade | Hold (Buy) |
47.73 (43.07) |
-9.76% | Details | |
| 12/2/2025 | Eli Lilly | LLY | Maintain | Hold (N/A) |
|
Details | ||
| 9/17/2025 | Eli Lilly | LLY | Downgrade | Hold (Buy) |
748.19 (1115.70) |
49.12% | Details | |
| 6/3/2025 | GlaxoSmithKline | GSK | Downgrade | Hold (Buy) |
41.03 (48.13) |
17.3% | Details | |
| 3/27/2025 | Pfizer | PFE | Maintain | Hold (N/A) |
|
Details | ||
| 1/16/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/2/2024 | GlaxoSmithKline | GSK | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 7/11/2024 | Novo Nordisk | NVO | Maintain | Hold (N/A) |
|
Details | ||
| 7/11/2024 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 6/20/2023 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 5/25/2023 | Pfizer | PFE | Maintain | Hold (N/A) |
|
Details | ||
| 1/30/2023 | Pfizer | PFE | Maintain | Hold (N/A) |
|
Details | ||
| 11/22/2022 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2021 | Eli Lilly | LLY | Upgrade | Buy (Hold) |
233.94 (748.19) |
219.82% | Details |
